Anticancer Therapies – Products

Network consists of 27 institutions with the goal of making effective immunotherapy agents broadly available for treatment of cancer.

Phase IIa study will investigate the optimal schedule for delivery of CYT107 and its ability to prevent or reverse the effects of chemotherapy-induced lymphopenia characterized by a low CD4 T cell count, identified as an independent prognostic factor for overall survival in patients with advanced cancers.

RTCA HT Instrument´s design allows for integration with automated plate and liquid handling systems.

Collection of 53 models offers full range of characterization.

The five-year extension of the alliance will allow both companies to offer unrivalled expertise in cancer research to their pharmaceutical clients.

Targeted antibody bavituximab to be evaluated in combination with pemetrexed and carboplatin for front-line non-small cell lung cancer.

MDV3100 continues to show durable antitumor activity as evaluated by median times to prostate-specific antigen progression and radiographic progression.

LungExpress Dx™ is a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage NSCLC.

L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic, non-small cell lung cancer.

U.S. patent and trademark office has issued an official notice of allowance for a new U.S. patent specific to the DPX-0907 therapeutic cancer vaccine.